Upgrade to SI Premium - Free Trial

Guggenheim Reiterates Buy Rating and $55 PT on Valeant Pharmaceuticals (VRX) Following 4Q Beat; 'Growth Prospects Underappreciated'

February 28, 2017 3:30 PM
Guggenheim analyst Louise Chen reiterates Buy rating and $55 price target on Valeant Pharmaceuticals (NYSE: VRX), suggesting muted upside in ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Analyst EPS View

Next Articles